1 / 4

Comparing Standard vs High-Dose Clopidogrel After PCI: Results from the GRAVITAS Trial

This study evaluates the efficacy of high-dose versus standard-dose clopidogrel in patients with high on-treatment platelet reactivity after PCI. The multicenter randomized trial focused on patients with PCI using 1 or more DES for stable CAD or non-STEMI. The primary endpoint was MACE at 6 months, including cardiac death, MI, and stent thrombosis. Safety was assessed based on severe or moderate bleeding according to the GUSTO definition. The conclusion indicated that high-dose clopidogrel did not significantly reduce the incidence of MACE or bleeding compared to the standard dose in this patient population. (Word count: 86)

Download Presentation

Comparing Standard vs High-Dose Clopidogrel After PCI: Results from the GRAVITAS Trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Standard vs High-dose Clopidogrelafter PCI: GRAVITAS Objective: to evaluate high-dose with standard dose clopidogrel in patients with high on-treatmentplateletreactivity (≥230 PRU) after PCI Study: multicenterrandomized double-blind trialPopulation: patients with PCI with 1 or more DES for stable CAD or non-STEMI Endpoint: MACE: cardiacdeath, MI, stentthrombosisat 6 monthsSafety: severe or moderatebleeding (GUSTO definition)

  2. Standard vs High-dose Clopidogrelafter PCI: GRAVITAS

  3. Standard vs High-dose Clopidogrelafter PCI: GRAVITAS

  4. Standard vs High-dose Clopidogrelafter PCI: GRAVITAS Conclusion high-dose clopidogreldoes not reduce incidence of MACE or bleedingcompared to standard dose in patients with high on-treatmentreactivity Price JAMA 2011;305:1097-1105

More Related